01 October 2018
Visiongain has launched a new pharma report: Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2018: Financial Performances, Services, Capacities, Mergers & Acquisitions, SWOT Analysis.
Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the benefits of contract manufacturing - lower costs, increased flexibility and external expertise - to focus resources on core competencies in drug development and marketing. CMOs are increasingly seen as a strategic partner for pharmaceutical companies, providing a one-stop-shop of services for formulation development and manufacturing throughout the lifecycle of a drug. The market-leading CMOs have grown through acquisitions and site expansions to offer almost all required services on a global scale. However, there is still a role to be played by specialist CMOs, particularly those that offer biological drug manufacturing services.
This updated study discusses market-leading companies worldwide, as well as the strategies they have employed to develop in recent years. Visiongain’s research and analysis explore opportunities and challenges for the top 50 pharma contract manufacturing organisations.
The lead analyst of the report commented "Visiongain has identified two major trends for leading API manufacturers in the coming 10 years: generics and HPAPIs. Demand for generic drugs is rising in developed markets - driven by the need to cut healthcare spending and patent expiries for major blockbusters - and in emerging markets - driven by rising disease prevalence and greater access to healthcare.
Demand will also rise for custom API manufacturing, particularly in the complex API and HPAPI market sectors. Visiongain believes that this market trend will be driven by increasing demands for targeted, small molecule therapies in chronic diseases, such as cancer."
Leading companies featured in the report include AbbVie Contract Manufacturing, Aenova Group, Aesica Pharmaceuticals, Ajinomoto Althea, Inc., Albany Molecular Research, Inc., Alcami Corporation, Alkermes plc, Almac Group, Amatsigroup, Aurobindo Pharma Ltd., Avid Bioservices Inc., Bayer AG, Baxter Biopharma Solutions, Biomay AG, Boehringer Ingelheim GmbH, Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Cardinal Health, Corden Pharmaceutical, Daito Pharmaceutical, Delpharm, Divis Laboratories Ltd., Dr. Reddy’s Laboratories Ltd., DPT Laboratories, Esteve Química, Evonik Degussa, Famar Health Care Services, Fareva, Fujifilm Diosynth Biotechnologies UK Ltd, GlaxoSmithKline plc, Huapont Medical, Lonza Group Ltd., Nipro Corporation, Paragon Bioservices Inc, Patheon Inc, Pfizer Inc./Pfizer CentreSource (PCS), Piramal Healthcare L, Recipharm A, Roche, Royal DSM NV, Shandong Xinhua Pharmaceutical, Siegfried, Teva API, Therapure Biopharma Inc., UPM Pharmaceuticals Inc., Vetter Pharmacuticals, Xcelience LLC, Xcellerex LLC, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceuticals
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Growing demand for contract manufacturing services; concentrating on core competencies of pharmaceutical and biopharmaceutical companies; and increasing demand for biosimilars and generics are key factors driving the global CRO regulatory services for the generic and biosimilar drug market.
12 August 2020
Increasing pollution in emerging economies has resulted in degradation of air quality which is one of the major reasons for increasing COPD and asthma prevalence amongst children and teenagers.
11 August 2020
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.
10 August 2020
Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.